Navigation Links
Anadys Pharmaceuticals to Present at the BMO Capital Markets Healthcare Conference
Date:7/30/2010

SAN DIEGO, July 30 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will present at the BMO Capital Markets 10th Annual Focus on Healthcare Conference on Thursday, August 5, 2010 at 1:15 p.m. EDT (10:15 a.m. PDT).  The conference is being held at the Sheraton New York Hotel & Towers.  Steve Worland, Ph.D., President and Chief Executive Officer of Anadys, will provide an overview of Anadys and its clinical development programs.

The corporate presentation will be simultaneously webcast and can be accessed on the Investor Relations page of the Company's website at www.anadyspharma.com.  Listeners are encouraged to visit the website approximately five minutes prior to the corporate presentation to download or install any necessary software.  A replay of the presentation will be available approximately one hour after the live webcast concludes and will be available through August 19, 2010.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C. The Company believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of new medicines. The Company is de
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
6. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
7. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
8. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
10. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... March 5, 2015 Bayer HealthCare announced today ... Conquer Cancer Foundation of the American Society of Clinical ... information technology platform designed to unlock vast quantities of ... "Bayer is proud to join ASCO ... leverage Big Data to help people whose lives have ...
(Date:3/5/2015)... NEW YORK , March 5, 2015 /PRNewswire/ ... real-time patient management solutions recognized for improving the ... announced today that Robert Anazagasty and ... Anazagasty will serve as Vice President, Strategic Client ... Enterprise Sales. These additions support AMC Health,s commitment ...
(Date:3/5/2015)... , March 5, 2015 LUNGevity ... the Food and Drug Administration,s (FDA) approval of ... Opdivo and other immunotherapy treatments add another critical ... harnessing the power of a patient,s own immune ... has been approved specifically for patients with squamous ...
Breaking Medicine Technology:Bayer HealthCare Contributes $1 Million to Support Cancer Care Technology Platform 2Bayer HealthCare Contributes $1 Million to Support Cancer Care Technology Platform 3AMC Health Bolsters Sales Team with Robert Anazagasty and Jared Wilstead 2AMC Health Bolsters Sales Team with Robert Anazagasty and Jared Wilstead 3LUNGevity Foundation Applauds FDA Approval of Immunotherapy Drug Opdivo 2LUNGevity Foundation Applauds FDA Approval of Immunotherapy Drug Opdivo 3
... 23, 2012  AlloSource, one of the nation,s largest non-profit ... use in surgical procedures and the world,s largest processor ... Dale Bike as Vice President of Sales and Marketing. ... Sales and Marketing, Dale will lead the AlloSource direct ...
... The Academy of Managed Care Pharmacy (AMCP) has installed ... elected members: President-Elect Kim A. Caldwell and Directors David ... members on the new Board of Directors are: President ... Directors Steve Avey and Eric Cannon. All of the ...
Cached Medicine Technology:Industry Veteran Brings Sales Expertise to AlloSource's Growing Distribution Network 2Academy of Managed Care Pharmacy (AMCP) Installs 2012-2013 Board of Directors 2Academy of Managed Care Pharmacy (AMCP) Installs 2012-2013 Board of Directors 3Academy of Managed Care Pharmacy (AMCP) Installs 2012-2013 Board of Directors 4
(Date:3/6/2015)... 2015 Medical Products, Inc., a Mississippi ... with GE Healthcare to become an authorized distributor for ... , MPI has 31 years in distribution within the ... With this agreement, MPI will have the opportunity to ... industry. , MPI has always strived to provide ...
(Date:3/5/2015)... In 2014, the FDA approved 44 drugs, with ... scoring 4 drug approvals in the USA. The infectious ... drug products, followed by oncology therapy with 18% of ... CDK inhibitors keep on attracting large-cap pharmacos. Nivolumab and ... metastatic melanoma, and at present, they are being investigated ...
(Date:3/5/2015)... 2015 A Bakersfield, Calif. state court jury ... trial awarding the plaintiff Coleen M. Perry a total of ... a TVT-Abbrevo pelvic mesh sling device, manufactured by Ethicon, Inc., ... , a partner at Wagstaff & Cartmell in ... plaintiff, along with Rich Freese and Tim Goss of ...
(Date:3/5/2015)... Kearney, Nebraska (PRWEB) March 05, 2015 ... rebranding of their practice including the brand’s new logo ... aims to showcase the practice’s modern approach to expert ... will be mobile-optimized and be built to be a ... referring physician community. With automated forms, communication and referral ...
(Date:3/5/2015)... March 05, 2015 On March 2, ... Augmentation, Labiaplasty on the Rise, Plastic Surgeons Say,” that ... American Society for Aesthetic Plastic Surgery and ... groups reported a year-over-year doubling of surgical butt augmentations ... quoted in the article, this increase can be attributed ...
Breaking Medicine News(10 mins):Health News:World Pharma Business and Large-Cap Companies Discussed by MP Advisors in In-demand Study Available at MarketPublishers.com 2Health News:World Pharma Business and Large-Cap Companies Discussed by MP Advisors in In-demand Study Available at MarketPublishers.com 3Health News:Client Wins $5.7 Million in TVT-Abbrevo Verdict against Johnson & Johnson in California State Court 2Health News:Central Nebraska Imaging Center Gets Rebranding 2Health News:The Kim Kardashian and Jennifer Lopez Effect: Butt Augmentations Double from 2013 to 2014 2
... HealthDay Reporter , MONDAY, Oct. 11 (HealthDay News) -- ... study involving human embryonic stem cells has been injected ... The patient, being cared for at the Shepherd Center ... injury. The center specializes in treating these types of ...
... outreach program staffed by current and former sex workers ... drug treatment among women in street-based sex work, according ... Excellence in HIV/AIDS (BC-CfE) and the University of British ... peer-reviewed medical journal Drug and Alcohol Dependence, ...
... cancer can lead some people to wonder if their risk ... than 85,000 postmenopausal women observed that regular physical activity, maintaining ... risk for women with, and without a family history of ... published online Oct. 12, 2010, by the journal Breast ...
... cancer who experience pain or depression also have a ... mouth and nausea, according to a report in the ... , one of the JAMA/Archives journals. Having many ... patients in primary care settings and those with chronic ...
... by the body becomes less effective in reducing blood ... risk of stroke in individuals without diabetes, according to ... of Neurology , one of the JAMA/Archives journals. ... sedentary lifestyle and obesity, according to background information in ...
... (AMD)including an intravitreous (into the eye) injection of a ... for use against the eye diseasedo not appear to ... or death when compared with existing therapies, according to ... of Ophthalmology , one of the JAMA/Archives journals. ...
Cached Medicine News:Health News:First Patient Treated in U.S.-Approved Embryonic Stem Cell Trial 2Health News:First Patient Treated in U.S.-Approved Embryonic Stem Cell Trial 3Health News:Peer-based outreach services for sex workers assist entry into detox and drug treatment 2Health News:Peer-based outreach services for sex workers assist entry into detox and drug treatment 3Health News:Breast-healthy lifestyle worthwhile, URMC study confirms 2Health News:Physical symptoms common, disabling among patients with cancer and pain or depression 2Health News:Insulin resistance may be associated with stroke risk 2Health News:Insulin resistance may be associated with stroke risk 3Health News:Certain new therapies for age-related eye disease do not appear to increase heart risks 2
Wire mesh braided design with a platinum core....
... Finnpipette Focus multichannel pipettes ... of reagents into microplates, ... 0.1-10 l volumes. The ... Finnpipette Focus multichannels, combined ...
... The Finnpipette Digital Multichannel, ... even lighter work of routine ... all these advanced features: Soft-touch ... micro volume pipetting (0.5-10ul models), ...
... and Benefits: 1-12channel pipette This ... product number, created to easily ... showing no availability yet, please ... number (Z37,173-4) or contact customer ...
Medicine Products: